RAB31 and breast carcinoma: Recent research has shown that RAB31 is capable of inhibiting the TGF-β pathway by decreasing TGFB1 mRNA and antigen levels, thereby exerting an impact on the migration, invasion, and apoptosis of breast cancer cells (82).